Overview


Antihemophilic factor (AHF or FACTOR VIII) is a crucial medication to prevent or manage bleeding episodes in individuals with hemophilia A. Additionally, it is employed during surgical procedures in these patients. Some variants of this product also serve in treating von Willebrand's disease. The administration of this medicine involves injection into a vein, typically performed by a healthcare professional in a clinical setting. In cases where it's prescribed for home use, patients will receive detailed instructions on the correct injection technique, which should be strictly adhered to. It's crucial to consult a pediatrician regarding its use in children, as special considerations may be necessary. While this drug may be prescribed for children of all ages under specific conditions, observing necessary precautions is essential.

Patients using products derived from human plasma should be aware of a slight risk of potential viruses or bacteria, although rigorous processing is undertaken to eliminate most of these contaminants. In case of concerns regarding viral infections, discussing them with a healthcare provider is recommended. Regarding side effects, any allergic reactions like swelling of the face, lips, or tongue, skin rash, chest pain, irregular heartbeat, faintness, flu-like symptoms, numbness or tingling, injection site reactions, severe weakness or fatigue, and jaundice should be promptly reported to the doctor.

FutureWise Market Research has published a report that provides an insightful analysis of Antihemophilic Factor Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Antihemophilic Factor Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Shire (Baxter)
  • Bayer
  • CSL
  • Pfizer
  • Grifols
  • Biogen
  • Octapharma
  • NovoNordisk
  • Greencross
  • Kedrion

(Note: The list of the major players will be updated with the latest market scenario and trends)

The market is driven by the rising incidence of hemophilia, a genetic bleeding disorder characterized by the deficiency of blood-clotting proteins. As awareness and diagnostic capabilities improve, more cases are being identified, thus fuelling the demand for antihaemophilia products. Ongoing research and development efforts have led to significant advancements in treating hemophilia. The introduction of novel therapies, including gene therapies and extended half-life factor replacement products, has revolutionized the landscape, offering more practical and convenient treatment options. In addition, governments and healthcare organizations across the globe have implemented programs to improve access to treatment for hemophilia patients. These initiatives often involve subsidies, financial assistance, and improved infrastructure for diagnosis and treatment, thereby driving market growth.

However, the cost associated with hemophilia treatment, especially with advanced therapies like gene therapy, can be substantial and poses a significant financial burden on patients and healthcare systems, potentially limiting access to these innovative treatments. Limited access to advanced hemophilia treatments in certain developing regions due to cost, infrastructure, and awareness can restrain market growth. Some individuals with hemophilia may develop inhibitors, which are antibodies that neutralize the effects of factor replacement therapies. This can complicate treatment and necessitate alternative approaches, potentially affecting market growth.

By Product Type

  • Recombinant Factor VIII
  • Plasma-derived Factor VIII

By Application

  • Hospital
  • Pharmacy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. n 2022, North America dominated the market share due to the escalating prevalence of haemophilia, leading to a heightened demand for antihemophilic factor within the region. The growing population of elderly individuals, who are more susceptible to bleeding disorders, further contributes to the demand for antihaemophilia factor. The region also benefits from an expanded healthcare infrastructure, augmented healthcare spending, and a surge in research and development activities. These efforts have resulted in innovative advancements in treatment modalities, reinforcing the market's growth trajectory.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Antihemophilic Factor Market By Product Type, By Application and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization services offered are free of charge with purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction

    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Methodology

    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data From Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study

  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Antihemophilic Factor Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards And Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Antihemophilic Factor Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Antihemophilic Factor Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Recombinant Factor VIII
        2. Plasma-derived Factor VIII

  • 8.   Global Antihemophilic Factor Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Hospital
        2. Pharmacy

  • 9.   North America Antihemophilic Factor Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million) along with expected regulatory needs

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Europe Antihemophilic Factor Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Switzerland
         2.9. Rest of Western Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 11.   Asia Pacific Antihemophilic Factor Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million) - along with expected regulatory needs

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. Singapore
         2.4. India
         2.5. Australia and New Zealand
         2.6. ASEAN
         2.7. South Korea
         2.8. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 12.  Latin America Antihemophilic Factor Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.  Middle East and Africa Antihemophilic Factor Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million) along with expected regulatory needs

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.  Market Share Analysis and Competitive Landscape

    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 15.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)

    •     1. Shire (Baxter)
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Bayer
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. CSL
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Pfizer
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Grifols
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Biogen
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Octapharma
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. NovoNordisk
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Greencross
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Kedrion
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 16.  Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated
      by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.  FutureWise SME key takeaway points for Client

    •   


Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11